Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 10, 2023
Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.
Journal: Cancer chemotherapy and pharmacology
Published: February 10, 2023
A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond.
Journal: Cancer medicine
Published: December 10, 2021
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Journal: Gynecologic oncology
Published: November 13, 2017
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.
Journal: British journal of cancer
Published: November 23, 2015
Showing 1-5 of 5
Last Updated: 09/26/2026